A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection
Year: 2015
Type: article
Abstract: While most hepatitis C virus (HCV) treatment studies have focused on genotypes 1–3, genotype 4 studies are lacking, even though it is common in the Middle East and Africa and has a growing prevalence elsewhere [1,2]. The most effective genotype 4 treatment currently approved is peginterferon (PegIFN)/ribavirin with sofosbuvir. However, both PegIFN and ribavirin carry a significant tolerability burden, and there remains a need for effective and better tolerated all-oral combinations for genotype 4 treatment.
Source: Journal of Hepatology
Authors: Tarek Hassanein, Karen D. Sims, Michael Bennett, Norman Gitlin, Eric Lawitz, Tuan Nguyen, Lynn Webster, Zobair Younossi, Howard Schwartz, Paul J. Thuluvath, Helen Zhou, Bhaskar Rege, Fiona McPhee, Nannan Zhou, Megan Wind-Rotolo, Ellen Chung, Amber Griffies, Dennis M. Grasela, David F. Gardiner
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,500
OpenAlex ID: W2010380636